Compare Johnson & Johnson (JNJ) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Snowflake Inc — how do they compare? Johnson & Johnson trades at $249.39 (market cap $598.96B), while Snowflake Inc trades at $270.32 (market cap $95.09B). The key difference: Johnson & Johnson is far larger — about 6.3× Snowflake Inc's market cap, and Johnson & Johnson pays a 2.15% dividend while Snowflake Inc pays none. Which is the better fit depends on your goals.
| JNJ | SNOW | |
|---|---|---|
Market Cap | $598.96B | $95.09B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $280.16 |
52-Week Low | $164.36 | $121.11 |
Enterprise Value | $631.90B | $94.90B |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Snowflake (SNOW) trades at $274.09, up 1.93% with bullish technical indicators and strong analyst support. The stock shows consistent earnings beats with Q1 2026 EPS of $0.39 exceeding expectations of $0.3193. Revenue growth remains robust at $3.63 billion in 2025, though the company continues to operate at a net loss of -$1.29 billion. Technical analysis indicates bullish momentum with current price near resistance at $274, while institutional sentiment remains positive with 81% buy ratings.
Snowflake presents a growth investment opportunity with accelerating AI Data Cloud adoption and 30% revenue growth targets, but faces significant execution risks from persistent losses and intense cloud competition. The consensus price target of $299.58 suggests 9% upside potential, though profitability challenges and high valuation multiples require careful monitoring of margin improvement trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
